Quantcast

Latest Hepatitis C/co-infection with HIV Stories

2011-05-18 12:07:00

ABBOTT PARK, Ill., May 18, 2011 /PRNewswire/ -- Abbott announced today that it has received approval from the U.S. Food and Drug Administration to market its RealTime PCR (polymerase chain reaction) test for measuring the viral load of hepatitis C (HCV), the leading cause of liver cancer in the United States. The Abbott RealTime HCV assay, developed for use on the Abbott m2000 system, is intended for use as an aid in the management of HCV-infected patients undergoing antiviral therapy....

2011-05-14 13:20:00

WHITEHOUSE STATION, N.J., May 14, 2011 /PRNewswire/ -- Merck (NYSE: MRK) (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has approved VICTRELIS(TM) (boceprevir), the company's innovative new medicine for the treatment of chronic hepatitis C (CHC). VICTRELIS is approved for the treatment of CHC genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients (18 years of age and older) with...

2011-05-13 16:15:00

SILVER SPRING, Md., May 13, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Victrelis (boceprevir) to treat certain adults with chronic hepatitis C. Victrelis is used for patients who still have some liver function, and who either have not been previously treated with drug therapy for their hepatitis C or who have failed such treatment. Victrelis is approved for use in combination with peginterferon alfa and ribavirin. (Logo:...

2011-05-09 14:04:40

Health outcomes explored at DDW 2011 Research being presented at Digestive Disease Week® (DDW) shows that screening individuals for hepatitis C based on age instead of conventional risk factors may help increase detection rates as well as prevent liver disease. Additionally, the rate of vaccination against viral hepatitis in patients with chronic liver disease and type 2 diabetes is relatively low, and these patients are at increased risk of severe liver injury once...

2011-05-09 08:15:00

SAN DIEGO, May 9, 2011 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD) announces that it has submitted a request to the U.S. Food and Drug Administration (FDA) for a face-to-face meeting to discuss re-initiation of an Investigational Device Exemption (IDE) study of the Aethlon Hemopurifier® in the United States. As part of these discussions, Aethlon management will present FDA officials with new clinical data that supports the safety of the...

2011-05-09 07:39:14

(Ivanhoe Newswire) --Screening for hepatitis C based on age instead of conventional risk factors may help improve detection rates and prevent liver disease. New research shows that new detection practices are improving screening and treatment for liver diseases. According to new research from the Inova Fairfax Hospital, vaccination rates against viral hepatitis in patients with chronic liver disease and type 2 diabetes is relatively low. This is significant because these patients are at...

2011-05-05 15:05:00

SAN DIEGO, May 5, 2011 /PRNewswire/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C, today reported its program highlights and financial results for the first quarter ended March 31, 2011. "The ANA598 Phase IIb study currently underway will expand the profile of ANA598 in important ways," said Steve Worland, Ph.D., President and CEO of Anadys. "We expect to...

2011-04-26 08:00:00

RIDGEFIELD, Conn., April 26, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that enrollment has commenced at North American sites in its pivotal Phase 3 clinical trial program for BI 201335, the Company's investigational, oral protease inhibitor for the treatment of chronic hepatitis C virus (HCV). Phase 3 trials have begun recruiting to evaluate BI 201335 plus standard-of-care (SOC) in both treatment-naive and -experienced patients with chronic genotype-1...

2011-04-26 07:51:34

(Ivanhoe Newswire) -- Patients with the HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a new study. Previous studies have suggested that a "class of antiretroviral drugs (particularly protease inhibitors), Human immunodeficiency virus 1 (HIV-1) RNA levels, and low CD4+ lymphocyte counts are each associated with an increased risk of cardiovascular disease events, an important risk factor for heart failure,"...

2011-04-25 16:57:23

Patients with HIV infection without a prior history of coronary heart disease may be at a higher risk of developing heart failure, according to a report in the April 25 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. Previous studies have suggested that "class of antiretroviral drugs (particularly protease inhibitors), Human immunodeficiency virus 1 (HIV-1) RNA levels, and low CD4+ lymphocyte counts are each associated with an increased risk of cardiovascular...


Latest Hepatitis C/co-infection with HIV Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »
Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related